Acquisition by Hanish Arnold C of 20500 shares of Salarius Pharmaceuticals at 0.5711 subject to Rule 16b-3
SLRX Stock | USD 1.43 0.02 1.38% |
Slightly above 55% of Salarius Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Salarius Pharmaceuticals suggests that some traders are interested. Salarius Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Salarius Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Salarius |
Filed transaction by Salarius Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Salarius Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Salarius Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Salarius Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Salarius Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Salarius Pharmaceuticals Fundamental Analysis
We analyze Salarius Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Salarius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Salarius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Salarius Pharmaceuticals is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Salarius Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Salarius Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Salarius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Salarius Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Salarius Pharmaceuticals Related Equities
AKTX | Akari Therapeutics | 8.04 | ||||
ALRN | Aileron Therapeutics | 4.38 | ||||
VCNX | Vaccinex | 2.44 | ||||
ARTL | Artelo Biosciences | 1.94 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
SABS | SAB Biotherapeutics | 1.02 | ||||
NTRB | Nutriband | 1.03 | ||||
AFMD | Affimed NV | 1.05 | ||||
GOVX | GeoVax Labs | 2.58 | ||||
PIRS | Pieris Pharmaceuticals | 3.45 | ||||
CRVS | Corvus Pharmaceuticals | 3.50 |
Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.